Evaluation of clinical outcomes among nonvalvular atrial fibrillation patients treated with rivaroxaban or warfarin, stratified by renal function
.

@article{Weir2018EvaluationOC,
  title={Evaluation of clinical outcomes among nonvalvular atrial fibrillation patients treated with rivaroxaban or warfarin, stratified by renal function
.},
  author={Matthew R. Weir and Lloyd P Haskell and Jeffrey S. Berger and Veronica Ashton and François Lalibert{\'e} and Concetta Crivera and Kip Brown and Patrick Lefebvre and Jeffrey R. Schein},
  journal={Clinical nephrology},
  year={2018},
  volume={89 5},
  pages={
          314-329
        }
}
BACKGROUND Renal dysfunction increases the risk of thromboembolic and bleeding events in patients with nonvalvular atrial fibrillation (NVAF). MATERIALS AND METHODS Adult NVAF patients with ≥ 6 months prior to first warfarin or rivaroxaban dispensing were selected from the IMS Health Real-World Data Adjudicated Claims database (05/2011 - 06/2015) with electronic medical records. Ischemic stroke events, thromboembolic events (venous thromboembolism, myocardial infarction, or ischemic stroke… CONTINUE READING